[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639145":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":38,"responsibleParty":56,"collaborators":58,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group: IBD patients",null,"Routine blood and urine tests performed every 3 and 6 months: peripheral blood count, CRP, glucose, total cholesterol, LDL, HDL, TGL, sodium, potassium, magnesium, phosphorus, uric acid, vitamin D3, albumin, urea, creatinine, calprotectin, and urinalysis with creatinine\u002Falbumin ratio (ACR) assessment.\n\nAssessment of the urinary system in abdominal ultrasound.",[13],"Diagnostic Test: Prospective assessment of the prevalence of kidney disease and\u002For renal complications in patients with IBD\u002Fthe general population based on routine laboratory test and abdominal ultrasound.",{"label":15,"type":10,"description":11,"interventionNames":16},"Control group - patients without IBD",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DIAGNOSTIC_TEST","Prospective assessment of the prevalence of kidney disease and\u002For renal complications in patients with IBD\u002Fthe general population based on routine laboratory test and abdominal ultrasound.","No experimental intervention is performed. Participants undergo routine clinical evaluation, laboratory testing, urinalysis including albumin-to-creatinine ratio (ACR), and abdominal ultrasound as part of observational data collection.",[15,9],[24],{"name":25,"affiliation":26,"role":27},"Grażyna Rydzewska, Professor","National Medical Institute of the Ministry of the Interior and Administration, Clinic of Gastroenterology and Internal Diseases.","STUDY_DIRECTOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Krzysztof Jaroń, MD, MPharm","CONTACT","+48 477 22 12 40","krzysztof.jaron@pimmswia.gov.pl",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},"Konrad Lewandowski, Associate\u002FAssistant Professor","+ 48 477 22 12 40","konrad.lewandowski@pimmswia.gov.pl",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"National Medical Institute of the Ministry of the Interior and Administration, Clinic of Gastroenterology and Internal Diseases","RECRUITING","Warsaw","Warszawa","02-507","Poland","PL",{"type":48,"coordinates":49},"Point",[50,51],21.01178,52.22977,{"lat":51,"lon":50},[54],{"name":25,"role":31,"phone":32,"phoneExt":10,"email":55},"grażyna.rydzewska@pimmswia.gov.pl",{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[59,62,65,67,69],{"name":60,"class":61},"Poznan University of Medical Sciences","OTHER",{"name":63,"class":64},"Nicolaus Copernicus university Collegium Medicum, Bydgoszcz, Poland","UNKNOWN",{"name":66,"class":61},"Medical University of Lodz",{"name":68,"class":61},"Jagiellonian University",{"name":70,"class":61},"Medical University of Silesia","100639145","renal-dysfunction-in-patients-with-inflammatory-bowel-disease-and-the-general-population-nephro-ibd-100639145",false,"NCT07593352","Renal Dysfunction in Patients With Inflammatory Bowel Disease and the General Population (NEPHRO-IBD)","A Multicenter, Prospective, Observational Study Comparing the Prevalence of Renal Dysfunction in Adult Patient With Inflammatory Bowel Disease Between General Population: The NEPHRO-IBD Study.","NEPHRO-IBD","Inclusion Criteria:\n\n* Age over 18 years\n* Confirmed IBD based on the overall clinical picture and endoscopic examination, or no IBD (control group without IBD)\n* Consent to participate in the study\n* Cognitive abilities sufficient to complete the questionnaires\n\nExclusion Criteria:\n\n* diabetes\n* dysuric symptoms suggestive of urinary tract infections\n* in women, menstruation (urinalysis can be performed 3 days before the onset and 3 days after the end of menstruation)\n* refusal to participate in all procedures performed in the study\n* age under 18 or over 80\n* pregnancy\n* other serious comorbidities whose presence or exacerbation may cause abnormalities in laboratory tests suggesting kidney disease\n* previous surgery whose presence may cause abnormalities in laboratory tests suggesting kidney disease\n* extreme physical exertion within 7 days before the test (marathons, half-marathons, triathlons) and intense physical exertion - strength training - within 1 day before the test. \\[moderate physical exertion such as walking, swimming, or cycling is not a contraindication\\]. • Excessive alcohol consumption 14 days before the study\n* Inability to perform necessary tests: e.g., inability to perform an imaging test\n* Unavailability of data: if the study is based on registry data, exclusion of individuals for whom there is incomplete data\n* Dehydration\n* Use of nephrotoxic medications\\* within a month before and during the study\n* Use of angiotensin inhibitors, sartans, or flozins that were introduced into treatment within \\\u003C3 months\n\n  \\*Nephrotoxic drugs:\n* Nonsteroidal anti-inflammatory drugs (NSAIDs) - occasional use is not contraindicated, but use for ≥ 10 days is an exclusion criterion\n* Gold salts\n* Penicillamine\n* Interferon alpha\n* Antituberculosis drugs (rifampicin, ethambutol, isoniazid)\n* Pamidronate\n* Biseptol\n* Antiviral drugs (acyclovir)\n* Anticonvulsants (carbamazepine, diazepam, phenobarbital)\n* Cyclosporine A, tacrolimus\n* Chinese herbs\n* Oncology drugs (cisplatin)",true,"ALL","18 Years","80 Years",{"count":84,"type":85},6000,"ESTIMATED","OBSERVATIONAL","The NEPHRO-IBD study is a multicenter prospective observational study designed to evaluate the prevalence of renal dysfunction and renal complications in adult patients with inflammatory bowel disease (IBD) compared with individuals from the general population. Although extraintestinal manifestations are common in IBD, renal involvement remains relatively underrecognized and insufficiently studied.\n\nThe study will recruit approximately 6,000 participants, including 3,000 patients with confirmed IBD (Crohn's disease or ulcerative colitis) and 3,000 individuals without IBD serving as a control group. Participants will undergo routine clinical assessment, including laboratory tests, urinalysis with measurement of the albumin-to-creatinine ratio (ACR), and imaging evaluation of the kidneys and urinary tract. Disease activity in patients with IBD will be assessed using validated clinical indices.\n\nThe study will also evaluate the relationship between renal dysfunction and disease activity, medications used in IBD treatment, and comorbidities. The results of this study are expected to improve the understanding of renal complications in patients with IBD and support earlier identification and management of kidney disease in this population.",[89,90,91],"IBD and Renal Involement","Chronic Kidney Disease","Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)",[93,94,95,96,90,97,98,99],"IBD","Crohn's Disease","Ulcerative Colitis","Renal Dysfunction","Extraintestinal Manifestations","Renal Complications in IBD","Albumin-to-Creatinine Ratio","2026-05-13",{"date":102,"type":103},"2026-05-18","ACTUAL",{"date":105,"type":103},"2025-11-20",{"date":107,"type":85},"2026-12-30",{"name":5,"class":6},1]